Cargando…

Extent of use of long-acting injectable antipsychotics in children and adolescents within Indiana Medicaid

INTRODUCTION: Oral formulations of the antipsychotics aripiprazole, asenapine, lurasidone, olanzapine, paliperidone, quetiapine, and risperidone are indicated for use in pediatrics for several diagnoses. Long-acting injectable (LAI) antipsychotics are of interest in this special population because t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Modesitt, Taylor, Kubascik, Erica, Ott, Carol
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	College of Psychiatric & Neurologic Pharmacists 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125120/ https://www.ncbi.nlm.nih.gov/pubmed/30206502 http://dx.doi.org/10.9740/mhc.2018.09.202

Ejemplares similares

Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database
por: Voss, Erica A., et al.
Publicado: (2015)

Racial and ethnic differences in patterns of use and discontinuation of long-acting injectable antipsychotics using Medicaid claims data
por: Caballero, Joshua, et al.
Publicado: (2023)

Evaluation of adherence and persistence with oral versus long-acting injectable antipsychotics in patients with early psychosis
por: Titus-Lay, Erika N., et al.
Publicado: (2018)

Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic
por: Pilon, Dominic, et al.
Publicado: (2017)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

Association of Indiana’s Section 1115 Waiver With Medicaid Enrollment
por: Stimpson, Jim P., et al.
Publicado: (2019)

Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
por: Sathienluckana, Thanompong, et al.
Publicado: (2021)

Assessing the Impact of Indiana Public Law 194 on Curbing the Concurrent Opioid Prescribing for Indiana Medicaid Enrollees
por: Vivas-Valencia, Carolina, et al.
Publicado: (2023)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
por: Lindenmayer, JP
Publicado: (2010)

Long-acting Injectable Antipsychotics in First-episode Schizophrenia
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013)

Population pharmacokinetics and dosing of long-acting injectable antipsychotics
por: Kim, David D., et al.
Publicado: (2021)

Long-acting injectable antipsychotics during pregnancy: An update
por: Paraschakis, A., et al.
Publicado: (2021)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2023)

Opioid-Related Treatment Disparities Among Medicaid Enrollees in Indiana
por: Vivas-Valencia, Carolina, et al.
Publicado: (2023)

Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
por: Patel, R., et al.
Publicado: (2018)

Positive views on antipsychotic long-acting injections: results of a survey of community patients prescribed antipsychotics
por: Mace, Shubhra, et al.
Publicado: (2019)

Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients
por: Kamat, Siddhesh A, et al.
Publicado: (2015)

Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics
por: Lin, Ching-Hua, et al.
Publicado: (2019)

Clinical and economic impact of long-acting injectable antipsychotics in patients previously treated with short-acting oral antipsychotics
por: Kheloussi, Steven, et al.
Publicado: (2022)

Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder
por: DEVRİMCİ ÖZGÜVEN, Halise, et al.
Publicado: (2021)

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
por: Toja-Camba, Francisco José, et al.
Publicado: (2021)

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
por: Correll, Christoph U., et al.
Publicado: (2021)

The use of long-acting injectable antipsychotics in an acute psychiatric unit
por: Ortega-Hernández, G., et al.
Publicado: (2023)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
por: Wehring, Heidi J., et al.
Publicado: (2011)

Case Series Evaluating the Use of Combined Long Acting Injectable Antipsychotics in Three Patients Within Forensic Services
por: Moxon-Holt, Megan, et al.
Publicado: (2022)

Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic
por: Chue, Pierre
Publicado: (2007)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
por: Citrome, Leslie
Publicado: (2009)

What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review
por: Baeza, Inmaculada, et al.
Publicado: (2023)

Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons
por: Kim, Borah, et al.
Publicado: (2012)

Patients’ experiences of long-acting injectable antipsychotics: a qualitative study
por: Chiu, Lin-Ling, et al.
Publicado: (2019)

Tachycardia in patients treated with clozapine versus antipsychotic long-acting injections
por: Nilsson, Björn M., et al.
Publicado: (2017)

Attitudes of European physicians towards the use of long-acting injectable antipsychotics
por: Patel, Maxine X., et al.
Publicado: (2020)

Rating Opportunity for Long-Acting Injectable Antipsychotic Initiation Index (ROLIN)
por: Ifteni, Petru, et al.
Publicado: (2021)

Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia
por: Riboldi, Ilaria, et al.
Publicado: (2022)

Analysis of Oral versus Long-acting Injectable Antipsychotics in the Maintenance of Schizophrenia
por: Vasiliu, O.
Publicado: (2022)

T213. TREND OF LONG-ACTING INJECTABLE ANTIPSYCHOTICS USE IN ASIA: FINDINGS FROM REAP ANTIPSYCHOTIC STUDIES
por: Lin, Shih-Ku, et al.
Publicado: (2020)

Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised?
por: Paton, Carol, et al.
Publicado: (2022)

Effects of long-acting injectable antipsychotics versus oral antipsychotics on autonomic nervous system activity in schizophrenic patients
por: Suda, Akira, et al.
Publicado: (2018)

Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness
por: Llorca, Pierre Michel, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fka2v07mvghf5mm629mdv4nv29